2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-1-(3-fluorophenyl)ethanone | 871222-77-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-1-(3-fluorophenyl)ethanone
• 英文别名: 1-(3-fluorophenyl)-2-(1,3-dihydro-2H-benzimidazol-2-ylidene)ethanone；2-(1,3-dihydrobenzimidazol-2-ylidene)-1-(3-fluorophenyl)ethanone
• CAS: 871222-77-4
• 化学式: C₁₅H₁₁FN₂O
• 分子量: 254.264
• InChiKey: PUZXCZIWIRSSDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.39
• 重原子数：
  19.0
• 可旋转键数：
  2.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.13
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-1-(3-fluorophenyl)ethanone 、 3-(chlorosulfonyl)-4-fluorobenzoyl chloride 在 silica gel 、 ethyl acetate n-hexane 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以to obtain 5-[2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-3-(3-fluorophenyl)-3-oxopropanoyl]-2-fluorobenzenesulfonyl chloride (2.10 g)的产率得到5-[2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-3-(3-fluorophenyl)-3-oxopropanoyl]-2-fluorobenzenesulfonyl chloride
  参考文献：
  名称：

  Propane-1,3-dione derivative or salt thereof

  摘要：

  本发明旨在提供一种作为GnRH受体拮抗剂有用的复合物。发明人进一步研究了丙酮酸1,3-二酮衍生物。结果，他们确认，在具有2-(1,3-二氢-2H-苯并咪唑-2-基亚胺基)的丙酮酸1,3-二酮衍生物中，苯环或噻吩环取代为—SO2—R3基团的化合物具有出色的GnRH受体拮抗效果，并完成了本发明。由于本发明化合物具有强效的GnRH受体拮抗作用，因此对于治疗性激素依赖性疾病，特别是GnRH相关疾病非常有用。此外，由于本发明化合物在人体内具有出色的代谢稳定性和少量药物相互作用，因此具有作为上述疾病用药物的优良特性。

  公开号：

  US07960562B2
• 作为产物：
  描述：

  2-甲基苯并咪唑 、 间氟苯甲酰氯 在 三乙胺 、 吗啉 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 生成 2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-1-(3-fluorophenyl)ethanone
  参考文献：
  名称：

  PROPANE-1,3-DION DERIVATIVE OR SALT THEREOF

  摘要：

  公开号：

  EP1864976B1

文献信息

• Propane-1,3-Dione Derivative or Salt Thereof
  申请人：Hirano Masaaki

  公开号：US20090018177A1

  公开（公告）日：2009-01-15

  Compounds useful as GnRH receptor antagonists are provided. The present inventors have further examined propane-1,3-dione derivatives and confirmed as a result that a propane-1,3-dione having 2-(1,3-dihydro-2H-benzimidazol-2-ylidene), or a compound which has benzene or thiophene ring substituted with a group derived from 1-hydroxymethyl, shows excellent availability, in addition to its excellent GnRH receptor antagonism, thereby accomplishing the invention. Since the compound of the invention shows excellent availability, in addition to its strong GnRH receptor antagonism, it can be expected that it exerts superior drug effect in the living body, and it is useful for the treatment of sex hormone dependent diseases such as prostate cancer, breast cancer, endometriosis, uterine leiomyoma, benign prostatic hypertrophy and the like. In addition, since the compound of the invention is excellent in metabolic stability in human and also is less in drug interaction, it has more desirable properties as a medicament to be used for the aforementioned diseases.

  本发明提供了作为GnRH受体拮抗剂有用的化合物。本发明人进一步研究了丙酮酸-1,3衍生物，并确认结果为具有2-（1,3-二氢-2H-苯并咪唑-2-基）的丙酮酸-1,3或具有苯环或噻吩环，其被1-羟甲基衍生物取代的化合物，除了具有优异的GnRH受体拮抗作用外，还具有出色的可用性，从而完成了该发明。由于该发明的化合物除了具有强大的GnRH受体拮抗作用外，还具有出色的可用性，因此可以预期它在生物体内发挥出卓越的药效，并且对于治疗性激素依赖性疾病，例如前列腺癌，乳腺癌，子宫内膜异位症，子宫肌瘤，良性前列腺增生等，具有用处。此外，由于该发明的化合物在人体内具有优异的代谢稳定性并且药物相互作用较少，因此作为用于上述疾病的药物具有更理想的性质。
• BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF
  申请人：Hirano Masaaki

  公开号：US20100173946A1

  公开（公告）日：2010-07-08

  Compounds useful as GnRH receptor antagonists are provided. The present inventors have further examined propane-1,3-dione derivatives and confirmed as a result that a propane-1,3-dione having 2-(1,3-dihydro-2H-benzimidazol-2-ylidene), or a compound which has benzene or thiophene ring substituted with a group derived from 1-hydroxymethyl, shows excellent availability, in addition to its excellent GnRH receptor antagonism, thereby accomplishing the invention. Since the compound of the invention shows excellent availability, in addition to its strong GnRH receptor antagonism, it can be expected that it exerts superior drug effect in the living body, and it is useful for the treatment of sex hormone dependent diseases such as prostate cancer, breast cancer, endometriosis, uterine leiomyoma, benign prostatic hypertrophy and the like. In addition, since the compound of the invention is excellent in metabolic stability in human and also is less in drug interaction, it has more desirable properties as a medicament to be used for the aforementioned diseases.

  本发明提供了作为GnRH受体拮抗剂有用的化合物。本发明人进一步研究了丙酮酸1,3-二酮衍生物，并确认结果表明，具有2-(1,3-二氢-2H-苯并咪唑-2-基)的丙酮酸1,3-二酮，或者具有苯环或噻吩环取代自1-羟甲基衍生物的化合物，除了具有优异的GnRH受体拮抗作用外，还表现出优异的可用性，从而实现了本发明。由于本发明的化合物除了具有强大的GnRH受体拮抗作用外，还具有优异的可用性，因此可以期望它在生物体内发挥出更卓越的药效，对于治疗前列腺癌、乳腺癌、子宫内膜异位症、子宫肌瘤、良性前列腺增生等性激素依赖性疾病非常有用。此外，由于本发明的化合物在人体内代谢稳定性优异且药物相互作用较少，因此具有更理想的性质，可用作上述疾病的药物。
• PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT
  申请人：Astellas Pharma Inc.

  公开号：EP1752452A1

  公开（公告）日：2007-02-14

  Compounds useful as GnRH receptor antagonists are provided. The present inventors have further examined propane-1,3-dione derivatives and confirmed as a result that a propane-1,3-dione having 2-(1,3-dihydro-2H-benzimidazol-2-ylidene), or a compound which has benzene or thiophene ring substituted with a group derived from 1-hydroxymethyl, shows excellent availability, in addition to its excellent GnRH receptor antagonism, thereby accomplishing the invention. Since the compound of the invention shows excellent availability, in addition to its strong GnRH receptor antagonism, it can be expected that it exerts superior drug effect in the living body, and it is useful for the treatment of sex hormone dependent diseases such as prostate cancer, breast cancer, endometriosis, uterine leiomyoma, benign prostatic hypertrophy and the like. In addition, since the compound of the invention is excellent in metabolic stability in human and also is less in drug interaction, it has more desirable properties as a medicament to be used for the aforementioned diseases.

  提供了可用作 GnRH 受体拮抗剂的化合物。本发明者进一步研究了丙烷-1,3-二酮衍生物，结果证实，具有 2-(1,3-二氢-2H-苯并咪唑-2-亚基)的丙烷-1,3-二酮或苯环或噻吩环被来自 1-羟甲基的基团取代的化合物，除了具有出色的 GnRH 受体拮抗作用外，还显示出出色的可用性，从而实现了本发明。由于本发明的化合物除了具有很强的 GnRH 受体拮抗作用外，还显示出很好的可用性，因此可望在活体内发挥卓越的药效，可用于治疗性激素依赖性疾病，如前列腺癌、乳腺癌、子宫内膜异位症、子宫肌瘤、良性前列腺肥大等。此外，由于本发明的化合物在人体中的代谢稳定性极佳，药物相互作用也较少，因此作为治疗上述疾病的药物具有更理想的特性。
• EP1752452
  申请人：——

  公开号：——

  公开（公告）日：——
• US7709519B2
  申请人：——

  公开号：US7709519B2

  公开（公告）日：2010-05-04